MRNA Cumulative FCF
The running total of free cash flow across the series, showing cumulative cash generated to date.
Cumulative FCF
Latest: −$11.20B (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | −$1.34B |
| 2023Q2 | −$2.49B |
| 2023Q3 | −$4.23B |
| 2023Q4 | −$3.83B |
| 2024Q1 | −$5.01B |
| 2024Q2 | −$6.47B |
| 2024Q3 | −$8.18B |
| 2024Q4 | −$7.88B |
| 2025Q1 | −$9.03B |
| 2025Q2 | −$9.96B |
| 2025Q3 | −$10.84B |
| 2025Q4 | −$9.95B |
| 2026Q1 | −$10.64B |
| 2026Q2 | −$11.20B |
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
Revenue
EPS
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Cumulative FCF
Cumulative FCF
Cumulative FCF
Latest Cumulative FCF: −$11.20B (2026Q2); −12.5% YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, Cumulative FCF ranged from −$11.20B in 2026Q2 to −$1.34B in 2023Q1.